Biostar Pharmaceuticals, Inc.
Biostar Pharmaceuticals, Inc. (BSPM) Revenue
Annual & quarterly revenue history · segment & region breakdown
BSPM · revenue · updated Jun 9, 2026
Core revenue metrics
Trailing 12 monthsBiostar Pharmaceuticals, Inc. trailing twelve-month (TTM) revenue is $0.00B, a decrease of 91.21% year-over-year from $0.00B in FY2016.
Revenue trend
2016 – 2006 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2016-12-31 | $0.00B | -$0.02B | -91.21% |
| 2015-12-31 | $0.03B | -$0.03B | -55.83% |
| 2014-12-31 | $0.06B | +$0.01B | +16.48% |
| 2013-12-31 | $0.05B | +$0.00B | +6.92% |
| 2012-12-31 | $0.05B | -$0.04B | -46.37% |
| 2011-12-31 | $0.09B | +$0.01B | +14.65% |
| 2010-12-31 | $0.08B | +$0.03B | +50.44% |
| 2009-12-31 | $0.05B | +$0.02B | +57.23% |
| 2008-12-31 | $0.03B | +$0.02B | +113.45% |
| 2007-12-31 | $0.02B | +$0.01B | +176.49% |
About Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Biostar Pharmaceuticals, Inc. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Biostar Pharmaceuticals, Inc. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from Biostar Pharmaceuticals, Inc.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
BSPM revenue · 4 questionsBSPM's trailing twelve-month (TTM) revenue is $0.00B. That is a decrease of 91.21% year-over-year from $0.00B in FY2016.
▸ Source: FMP · Biostar Pharmaceuticals, Inc. SEC filings · GAAP · Biostar Pharmaceuticals, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026